Company / Depreciation & Amortization
Ovid Therapeutics Inc. Depreciation & Amortization History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$613.0K
FY2025
5-year range
$237.1K / $613.0K
FY2022-FY2025
Trend
+7.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Depreciation & Amortization has increased for 3 consecutive years, from $237,079 in FY2022 to $613,000 in FY2025.
Based on SEC 10-K filings.
$613,000 in FY2025 with a 3-year CAGR of +37.3%.
Increased from $512,505 to $613,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- +37.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Ovid Therapeutics Inc.'s depreciation & amortization has grown for 3 consecutive years.
- 3-year CAGR of +37.3%, indicating consistent growth.
- In FY2025, depreciation & amortization increased 7.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $613.0K | +7.9% |
| FY2024 | $568.0K | +10.8% |
| FY2023 | $512.5K | +116.2% |
| FY2022 | $237.1K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026